Searched for
ARUN SAWHNEY
Buy Triveni Turbine, target price Rs 435: Sharekhan by BNP ParibasTriveni Turbine., incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 12724.61 Crore) operating in Engineering s...- Ranbaxy CEO Arun Sawhney to retire on October 31Sawhney joined Ranbaxy in 2008, as the head of the API (active pharmaceutical ingredient) business and global manufacturing and supply chai...
- Ranbaxy merger: Sun Pharma readies new leadership teamKal Sundaram, who is CEO of North America business for Sun Pharma will lead the North American business for both the organisations.
- Minority shareholders approval not needed for Sun deal: RanbaxyOn April 7, Sun Pharmaceutical announced it will fully acquire the troubled Ranbaxy Laboratories in an all-stock transaction with a total e...
- Ranbaxy gets CDSCO nod to sell malaria drug 'SynriamTM'"This approval makes SynriamTM one of the few therapies in the world that successfully treats both, Plasmodium vivax and Plasmodium falcipa...
- Ranbaxy seeks to assuage shareholders' worries after USFDA banRanbaxy Laboratories today sought to assuage concerns of shareholders in the wake of company's stock price taking a hard knock.
- Ranbaxy’s drug Diovan's delay trims Novartis’ lossesRanbaxy, which holds 180-day exclusivity for the generic version of the drug, was originally schedule to launch the drug in the US market i...
- Ranbaxy, Daiichi to leverage on brand strength for global marketsIn a bid to strengthen their hybrid business model, Ranbaxy and its parent firm Daiichi Sankyo will project only one of them as the face of...
- We will continue on our growth plans: Arun Sawhney, Ranbaxy"Ranbaxy is the number one pharmaceutical company from India. We have inherently great strengths. "
- Credibility of Indian generics industry, Ranbaxy has not eroded: Arun Sawhney, CEO RanbaxySawhney acknowledges that questions will be raised but asserts that Ranbaxy will respond in most credible manner to ensure its brand image.
- I stand by safety of every Ranbaxy pill: Arun Sawhney, CEOI stand by every pill that the company markets across the world, days after the company pleaded guilty on drug safety charges in the US for...
- 'Former Ranbaxy shareholders hid key info on US investigation'Ranbaxy's Japanese promoters today blamed the company's former Indian owners for concealing and misrepresenting critical information about ...
- Ranbaxy has taken steps to ensure quality control: Arun SawhneyRanbaxy Laboratories today said it has taken several steps in recent years to ensure safety and efficacy of its products in the global mark...
- Ranbaxy Laboratories posts Q1 loss of Rs 586 croreThe company, however, hopes the launch of generic versions of two blockbuster drugs in the US will potentially boost revenues.
- Ranbaxy setting up plants in Nigeria, MalaysiaRanbaxy Laboratories today said it is setting up two new manufacturing facilities in Nigeria and Malaysia, as part of efforts to boost its ...
- Ranbaxy Laboratories's net profit zooms four-fold at Rs 1,246 croreRanbaxy net profit jumped four fold to Rs 1,246 cr for the quarter ended Mar, buoyed by gains from two exclusive drug launches in US.
- We are open to calculated risks and swift decisions: Arun Sawhney, CEO & MD, Ranbaxy LaboratoriesRanbaxy Laboratories has met several obligations mandated by the US drug regulator, but it is still uncertain when it can resume exports fr...
- Ranbaxy Laboratories closes plant in USRanbaxy Laboratories has closed a unit in the US as part of a rationalisation process. The plant was under scrutiny by US authorities for v...
- Arun Sawhney to replace Atul Sobti as Ranbaxy CEOSobti’s exit comes at a time, when the company seems to have seen the worst of its regulatory problems in the US which has dragged its reve...
- Atul Sobti to step down as Ranbaxy CEO & MD?Arun Sawhney, president global pharmaceutical business is seen as a contendor to take over Sobti's position. Sobti was more of an interim C...
Load More
